Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMBITION 3: weekly subcutaneous zenagamtide versus semaglutide in adults with inadequately controlled type 2 diabetes mellitus on metformin and/or an SGLT2 inhibitor
MOH_2026-07-08_016926Phase 3Not yet recruiting
- Sponsor
- Novo Nordisk
- Start
- Jun 2026
- Modality
- Recombinant Proteins and Enzymes, Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Zenagamtide, Semaglutide and Placebo (3 arms). Planned start Jun 2026; status: not yet recruiting.
02
Drugs
amycretinsemaglutide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on MOH_2026-07-08_016926.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2026-07-08_016926.